INTRODUCTION {#sec1}
============

Night-time arrhythmia and its complications remain an ambiguous scientific and therapeutic field of cardiology. The autonomic nervous system and various pathologic conditions are the key regulators of the cardiac rhythm during sleep ([@ref1]). Although most sleep-related arrhythmias are detected incidentally on Holter recordings and are benign, some, like rapid eye movement (REM) sleep-related bradyarrhythmia syndrome, are associated with serious adverse effects ([@ref2]). REM sleep-related bradyarrhythmia is a very rare syndrome characterized by bradyarrhythmic episodes and asystoles during REM sleep, and is not associated with sleep apnoea or hypoxia ([@ref3]). Since its first description by Guilleminault et al. in 1984, only few cases were reported in worldwide medical literature. Due to non-specific daytime symptoms such as faintness, light-headedness, and atypical thoracic pain, patients suffering from REM-related bradyarrhythmia are often underdiagnosed ([@ref3]). However, early recognition and appropriate therapy of REM sleep-related bradyarrhythmia can help prevent life-threatening consequences. We report a case of REM sleep-related bradyarrhythmia syndrome followed by hypertension and diastolic heart failure.

CASE REPORT {#sec2}
===========

A 49-year-old male was referred to the Cardiology Department due to frequent paroxysmal tachisystolic episodes of atrial fibrillation, dyspnoea, and snoring at night. The patient was overweight (BMI 33.9 kg/m^2^) and suffered from severe hypertension (blood pressure (BP) at rest 215/110 mmHg, mean 24 h BP 184/105 mmHg). He was treated with Valsartan/Hydrochlorothiazide 160/12.5 mg in the morning and Valsartan/Amlodipine 160/10 mg in the evening, and Torasemide 10 mg three times a week. Echocardiography revealed left ventricle (LV) hypertrophy (MMI-135 g/m^2^) and diastolic dysfunction (mean E/E' ratio 15). The exercise stress test was normal. Twentyfour-hour Holter ECG monitoring exhibited 40 episodes of bradycardia with minimal heart rate (HR) -- 21 beats/min and nine sinus arrest episodes with a maximal pause of 5.5 s. HR varied from 46--128 beats/min (avg. 95 beats/min). Episodes of bradycardia were frequent at night-time and tachycardia presented during day hours. Based on the complaints and preliminary test results, a diagnosis of obstructive sleep apnoea was suspected. However, polysomnography tested negative. The test showed a normal sleep structure with no evidence of hypoxia or sleep-apnoea (Apnoea-Hypopnoea Index (AHI) 1.8 events/h). Importantly, episodes of bradycardia were documented only during phasic events of REM sleep ([Fig. 1](#fig1){ref-type="fig"}). Poincare plot analysis of heart rate variability revealed an increased parasympathetic activity in the REM sleep phase compared to wakefulness, and NREM sleep stages 1--3 ([Fig. 2](#fig2){ref-type="fig"}). REM sleep-related bradyarrhythmia syndrome was diagnosed. The patient was treated with dual chamber heart pacemaker implantation. Beta-blockers were added for rhythm control. Treatment resulted in improvement of the patient's condition. His office BP lowered to 145/80 mmHg, mean 24 h BP reduced to 138/82 mmHg. Antihypertensive treatment regime remained unchanged.

DISCUSSION {#sec3}
==========

Although REM sleep-related bradyarrhythmia syndrome has drawn attention of sleep medicine specialists and arrhythmologists, the rareness of this syndrome results in poor literature data. To date, only 18 cases of REM sleep-related sinus arrest were identified according to a review published in 2011 ([@ref4]). However, intermittent nocturnal sinus arrest can be found in up to 39% of healthy asymptomatic adults, which suggests that REM sleep-related bradyarrhythmia may be a much more common entity than currently believed. Similarly to our case, the majority of identified cases of REM-related bradyarrhythmia syndrome were reported in young or middle-aged men. However, it is not yet known whether this reflects a sampling bias or indicates a physiological gender difference ([@ref4]).

The most common complication of sleep disorders is hypertension ([@ref5]). For example, 50--56% of individuals with obstructive sleep apnoea (OSA) are hypertensive, and an estimated 30--40% of hypertensive subjects have OSA ([@ref6]--[@ref9]). However, no cases of concomitant hypertension were previously described in REM sleep-related bradyarrhythmia syndrome. Instead, the most common complications include syncopes and an imminent threat of sudden cardiac death ([@ref2]).

![Polysomnography test. Paradoxical bradycardia and 5.5 s asystole in REM sleep stage](aml-25-001-g001){#fig1}

Our patient presented with night-time arrhythmias recorded during phasic events of REM sleep. In general, the nocturnal heart rate is determined by the interaction between parasympathetic and sympathetic nervous systems. The latter acts upon sleep state cycles, whereas the parasympathetic system is influenced by circadian rhythms ([@ref10]). Studies on healthy human volunteers suggest that stages of NREM sleep represent a continuum of increasing parasympathetic dominance from waking to deep sleep ([@ref11]). In contrast, REM sleep is characterized by sympathetic dominance and suppression of the parasympathetic nervous system indicated by significantly reduced heart rate variability ([@ref12]). REM sleep bradyarrhythmia is most likely caused by abnormal autonomic modulation: an increased vagal tone during phasic REM sleep with absence of normal compensatory sympathetic activity.

We hypothesize that our patient's hypertension was caused by a paradoxically abnormal autonomic nervous system control and explain it through the acetylcholine metabolism pathway. The main neurotransmitter of the parasympathetic nervous system is acetylcholine, which is produced from the interaction of choline and acetyl coenzyme A (CoA). The latter is produced in the glucose breakdown cycle; therefore, hypoglycaemia is one of the causes that lead to cholinergic deficit ([@ref13]). The combination of increased nocturnal vagal activity and nightly fasting may contribute to cholinergic depletion and subsequent autonomic dysregulation. Therefore, bradyarrhythmic episodes manifest due to increased vagal activity during REM sleep, and hypertension is caused by a paradoxical sympathetic overactivity with aberrant inhibition of parasympathetic system at the rest of the time. Our patient's increased mean 24 h heart rate and sinus tachycardia, as well as an effective beta-blocker therapy may confirm the hypothesis.

Although many sleep disorders can be diagnosed using medical history alone, our case of REM sleep-related bradyarrhythmia syndrome proves that common symptoms of sleep disorders overlap and REM sleep-related bradyarrhythmia might be confused with OSA. Our patient's Holter ECG test revealed sinus arrest episodes persisting up to 5.5 seconds. Long-lasting cardiac pauses are associated with REM sleep-related bradyarrhythmia syndrome and with OSA syndrome, which should therefore be ruled out when investigating nightly pauses ([@ref14]). However, REM sleep-related sinus arrests and atrioventricular (AV) blocks are not linked with episodes of apnoea or hypopnea. Therefore, overnight polysomnography is useful in assessing and distinguishing such disorders as OSA and REM sleep-related bradyarrhythmia syndrome ([@ref15]). Accurate differential diagnosis between OSA and REM sleep-related bradyarrhythmia syndrome is crucial in determining the right treatment strategy for the underlying disease and its complications.

![Sleep-time heart rate variability analysis by Poincaré plot illustrates an increased parasympathetic activity in REM sleep stage and sympathetic overactivity during the rest of the day](aml-25-001-g002){#fig2}

Many patients with REM sleep-related bradyarrhythmia syndrome are relatively asymptomatic and there currently is no standardized treatment for this condition ([@ref4]). Several drugs like atropine, protriptyline and amitriptyline that block vagal-cardiac input have been tried in a limited number of patients, but the success rate was elusive ([@ref16]). All patients treated with atropine or an anticholinergic agent had the drug discontinued due to adverse side effects ([@ref4]). Few experimental treatment options like selective vagotomy exist, but there currently is no reported data of its efficacy in humans ([@ref17]). Our patient was treated with the implantation of dual chamber heart pacemaker. The use of implantable cardiac pacemakers is the most common treatment strategy for REM sleep-related bradyarrhythmia syndrome ([@ref4]). According to the American College of Cardiology/American Heart Association guidelines ([@ref18]), pacemaker implantation is the only recommended class I indication for documented periods of asystole greater than or equal to 3.0 s, or any escape rate less than 40 beats per minute in awake, symptom-free patients with high-grade atrioventricular block and generally discouraged in the case of asymptomatic sinus arrests.

According to the literature, of the eight reported cases of REM-related sinus arrest, 75% were treated with implantable cardiac pacemakers. Of five patients with long-term follow-up, all were asymptomatic at a mean follow-up of 3.7 years ([@ref4], [@ref14], [@ref19]). After pacemaker implantation, our patient's condition also improved as episodes of night dyspnoea disappeared.

CONCLUSIONS {#sec4}
===========

REM sleep-related bradyarrhythmia syndrome often displays indistinct features, but it can also be asymptomatic. Autonomic nervous system derangements and acetylcholine metabolism disturbances influence the development of hypertension in REM sleep-related bradyarrhythmia syndrome. Implantation of heart pacemaker is an effective treatment for REM sleep-related bradyarrhythmia syndrome. Recognition and appropriate management of concomitant pathologies is crucial in achieving good outcomes for patients with REM sleep-related bradyarrhythmia syndrome.
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